WallStSmart
QNCX

Quince Therapeutics, Inc.

NASDAQ: QNCX · HEALTHCARE · BIOTECHNOLOGY

$1.26
-8.18% today

Updated 2026-06-05

Market cap
$17.80M
P/E ratio
P/S ratio
EPS (TTM)
$-9.67
Dividend yield
52W range
$1 – $46
Volume
46.7M

Quince Therapeutics, Inc. (QNCX) Financial statements

SEC filings — annual and quarterly data.

Cash flow — annual

Item201720182019202020212022202320242025
Operating cash flow$-9.83M$-11.70M$-33.28M$-50.82M$-62.93M$-44.04M$-18.29M$-31.90M$-41.42M
Capital expenditures$77000.00$212000.00$55000.00$52000.00$180000.00$133000.00$160000.00$257000.00$352000.00
Depreciation$45000.00$51000.00$188000.00$332000.00$344000.00$204000.00$322000.00$186000.00
Stock-based comp$38000.00$155000.00$2.06M$14.47M$29.85M$16.62M$5.22M$4.75M$5.11M
Free cash flow$-9.90M$-11.91M$-33.33M$-50.87M$-63.11M$-44.17M$-18.45M$-32.16M$-41.78M
Investing cash flow$-77000.00$-46.75M$-17.75M$-52.43M$58.95M$18.00M$-5.76M$21.91M
Financing cash flow$7.75M$75.93M$77.37M$118.88M$6.81M$707000.00$143000.00$-4.78M
Dividends paid
Share repurchases
Debt repayment
Net change in cash$-25.33M

Frequently asked questions

How much free cash flow does QNCX generate?

QNCX produced $-41.78M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is QNCX's balance sheet healthy?

QNCX holds $5.81M in cash and equivalents against — in long-term debt, on $-35.71M of shareholder equity. That debt is best read against the cash flow the business throws off each year.